Next Article in Journal
Previous Article in Journal
Mar. Drugs 2010, 8(10), 2647-2658; doi:10.3390/md8102647
Article

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis

* ,
,
,
,
 and
Received: 29 July 2010; in revised form: 24 September 2010 / Accepted: 12 October 2010 / Published: 13 October 2010
View Full-Text   |   Download PDF [118 KB, uploaded 13 October 2010]
Abstract: Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors. Development of distant metastasis is frequent, even in patients undergoing initial curative surgery. Trabectedin, a tetrahydroisoquinoline alkaloid isolated from the Caribbean marine tunicate Ecteinascidia turbinata, was approved in 2007 for patients with advanced STS after failure of anthracyclines and ifosfamide, or for patients unsuited to receive these agents. In this study, we retrospectively analyzed 25 patients who had been treated with trabectedin at our institution between 2007 and 2010. The majority (72%) had been heavily pre-treated with ³2 previous lines of chemotherapy. Response assessed by conventional RECIST criteria was low, with only one patient achieving a partial remission (PR) and 10 stable disease (SD) after three cycles of treatment. However, median progression-free survival (PFS) and overall survival (OS) were significantly prolonged in this population compared to non-responders, with 7.7 months versus 2.1 months (p < 0.0001; HR 15.37, 95% CI 4.3 to 54.5) and 12.13 months versus 5.54 months (p = 0.0137; HR 3.7, 95% CI 1.3 to 10.5), respectively. PFS for all patients was 58% at three months and 37% at six months. Side effects, including neutropenia, elevation of liver transaminases/liver function tests, and nausea/vomiting, were usually mild and manageable. However, dose reductions due to side effects were necessary in five patients. We conclude that trabectedin is an effective and generally well tolerated treatment for STS even in a heavily pre-treated patient population.
Keywords: trabectedin; soft tissue sarcoma; metastatic; advanced; chemotherapy trabectedin; soft tissue sarcoma; metastatic; advanced; chemotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Schmitt, T.; Keller, E.; Dietrich, S.; Wuchter, P.; Ho, A.D.; Egerer, G. Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis. Mar. Drugs 2010, 8, 2647-2658.

AMA Style

Schmitt T, Keller E, Dietrich S, Wuchter P, Ho AD, Egerer G. Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis. Marine Drugs. 2010; 8(10):2647-2658.

Chicago/Turabian Style

Schmitt, Thomas; Keller, Eva; Dietrich, Sascha; Wuchter, Patrick; Ho, Anthony D.; Egerer, Gerlinde. 2010. "Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis." Mar. Drugs 8, no. 10: 2647-2658.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert